NGNE Stock Overview
A biotechnology company, develops genetic medicines for rare neurological diseases.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 2/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Neurogene Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$40.27 |
52 Week High | US$53.00 |
52 Week Low | US$12.49 |
Beta | 0 |
11 Month Change | 14.99% |
3 Month Change | 32.82% |
1 Year Change | n/a |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 166.69% |
Recent News & Updates
Shareholder Returns
NGNE | US Biotechs | US Market | |
---|---|---|---|
7D | 6.2% | 2.4% | 3.0% |
1Y | n/a | 20.4% | 25.3% |
Return vs Industry: Insufficient data to determine how NGNE performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how NGNE performed against the US Market.
Price Volatility
NGNE volatility | |
---|---|
NGNE Average Weekly Movement | 12.4% |
Biotechs Industry Average Movement | 10.2% |
Market Average Movement | 6.4% |
10% most volatile stocks in US Market | 15.2% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NGNE has not had significant price volatility in the past 3 months.
Volatility Over Time: NGNE's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | 91 | Rachel McMinn | www.neurogene.com |
Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC.
Neurogene Inc. Fundamentals Summary
NGNE fundamental statistics | |
---|---|
Market cap | US$555.61m |
Earnings (TTM) | US$2.36m |
Revenue (TTM) | US$925.00k |
221.3x
P/E Ratio565.7x
P/S RatioIs NGNE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
NGNE income statement (TTM) | |
---|---|
Revenue | US$925.00k |
Cost of Revenue | US$52.98m |
Gross Profit | -US$52.05m |
Other Expenses | -US$54.41m |
Earnings | US$2.36m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.18 |
Gross Margin | -5,627.03% |
Net Profit Margin | 255.57% |
Debt/Equity Ratio | 0% |
How did NGNE perform over the long term?
See historical performance and comparison